



Many Symptoms, ONE TEST.




Add Clarity with AVISE CTD

The only validated test using the power of CB-CAPs—proven to outperform traditional biomarkers alone in the detection of SLE. Order AVISE CTD—the ideal test for your ANA+ referrals.

AVISE CTD – The Advanced Approach to a Differential Diagnosis of Connective Tissue Diseases

AVISE CTD is specifically designed to help Rheumatologists when distinguishing diseases in the presence of overlapping symptoms. And only AVISE CTD uses Cell-Bound Complement Activation Products (CB-CAPs), stable biomarkers of complement activation. Consider leveraging AVISE CTD as the logical next step for all your patients suspected of CTD.


AVISE CTD
48%
MORE SENSITIVE
than ds-DNA
for SLE¹



Unique Biomarkers


AVISE CTD includes patented and specialized biomarkers such as CB-CAPs. CB-CAPs are stable biomarkers reflecting the degree of complement activation and therefore useful information in the diagnosis of SLE. The included proprietary markers EC4d and BC4d demonstrate a 22% greater sensitivity over C3/C4 for SLE.

CB-CAPs
22%
MORE SENSITIVE
than C3/C4
for SLE¹



State-of-the-Art Methods

Accurate results depend on reliable test methods. That's why AVISE CTD tests ANA by IFA using digital imaging as well as ELISA, and confirms positive ds-DNA results using immunofluorescence Crithidia assay. All markers reported in AVISE CTD are carefully selected to provide maximum performance in the diagnosis of SLE and diseases that mimic lupus using a patented two tier algorithm.



Proprietary Index

AVISE CTD employs the use of a proprietary Index Calculation, turning isolated data points into actionable information². Developed using multivariate logistic regression, the index makes all SLE biomarker data clear and helps you provide a more confident diagnosis for your patients.

Proprietary Index Calculation turns isolated SLE data points into actionable information

AVISE CTD — Specifically designed to provide clarity and confidence



8 individual ENA markers to aid in differential CTD diagnosis



RA panel (including RF IgM, RF IgA, Anti-CCP, & Anti-CarP) to help rule-in rheumatoid arthritis



Anti-Phospholipid Syndrome biomarkers to help assess risk for thrombosis and cardiovascular events as well as guide SLE diagnosis



Thyroid panel to aid in diagnosis of Graves' Disease & Hashimoto's thyroiditis

"AVISE CTD helps to overcome the limitations of our traditional markers including ANA, dsDNA, or C3/C4 alone. CB-CAPs technology can improve the clinician's ability to diagnose lupus."

– Dr. Chaim Putterman

"The AVISE CTD test can be especially useful in assessing if your ANA+ fibromyalgia patients have underlying SLE or other inflammatory rheumatic diseases."

– Dr. Daniel J. Wallace



Start leveraging AVISE CTD for your patients today.
Visit www.AviseTest.com or call 888.452.1522.



- References:**
1. Putterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. *Lupus Science & Medicine* 2014;1:e000056. doi:10.1136/lupus-2014-000056.
 2. Mossell J, Goldman J, Barken D, et al. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus. *The Open Rheumatology Journal* 2016.